CONVINCE Trial Summary The abstract discusses the results of the CONVINCE trial, a randomized, controlled study comparing high-dose hemodiafiltration (HDF) with conventional high-flux hemodialysis (HD) in patients with end-stage kidney disease (ESKD). The trial aimed to determine whether high-dose HDF reduces the risk of death in ESKD patients compared to high-flux HD. Previous studies had […]
Category: Nephrology
AMPLITUDE-O Trial: CV and Renal Outcomes with Efpeglenatide
2021 AMPLITUDE-O TRIAL M Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes international, randomized, controlled trial Objective: To evaluate efpeglenatide in participants with type 2 diabetes and either a history of cardiovascular disease or current kidney disease 4076 patients Inclusion criteria: Participants ≥18 years of age with type 2 diabetes mellitus and history […]
DCP Trial Summary: HCTZ vs Chlorthalidone
2022 DCP TRIAL Chlorthalidone compared with hydrochlorothiazide for the preven- tion of cardiovascular events in patients with hypertension: The Diuretic Comparison Project (DCP) Open-label, pragmatic, randomized controlled trial Objective: To compare the differences between hydrochlorothiazide (HCTZ) compared with chlorthalidone in improving cardiovascular outcomes among patients with hypertension 13523 patients Inclusion criteria: Patients >65 years on […]
AMACING Trial Summary: IV Hydration for CIN
2017 AMACING TRIAL Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy. M Single-center, randomised, parallel-group, open-label, phase 3, non-inferiority trial 660 patients Objective: To evaluate the impact of prophylactic hydration with normal saline on rate of contrast-induced nephropathy in high-risk patients receiving contrast medium […]
AKIKI 2 Trial Summary: RRT for Severe AKI
2021 AKIKI 2 TRIAL Comparison of two delayed strategies for renal replacement therapy initiation for severe AKI Multicentre, open-label, randomised, controlled trial Objective: To test the hypothesis that a more-delayed initiation strategy would result in more RRT-free days, compared with a delayed strategy. Σ 278 patients Inclusion criteria: critically ill patients with severe acute kidney […]
ACT Trial Summary: Acetylcysteine before Angiography
ACETYLCYSTEINE FOR PREVENTION OF RENAL OUTCOMES IN PATIENTS UNDERGOING ANGIOGRAPHY – ACT TRIAL Multicenter, Double-blind, Randomized, Placebo-controlled Trial STUDY OBJECTIVE: To Assess the use of acetylcysteine for preventing contrast-induced acute kidney injury in patients undergoing angiography 2308 Adults with ≥1 risk factor for contrast induced-AKI undergoing coronary or peripheral arterial diagnostic angiography ACETYLCYSTEINE N = […]
ISCHEMIA-CKD Trial Summary: CAD Management in Advanced CKD
2020 ISCHEMIA-CKD TRIAL Management of coronary disease in patients with advanced kidney disease international, randomized controlled trial Objective: To compare the effectiveness of routine invasive therapy with optimal medical therapy among patients with stable coronary disease & advanced chronic kidney disease 777 Patients Inclusion criteria: Patients >20 years with at least moderate ischemia on noninvasive […]
Cut-off Haemofiltration With Standard Haemofiltration in Acute Renal Failure
2018 HIGH VS STANDARD CUTOFF HEMOFILTRATION IN AKI A Double-Blind RCT of High cutoff versus Standard Hemofiltration in critically ill patients with Acute Kidney Injury (AKI) Single-center, double-blind, randomized controlled trial Objective: To assess impact of High cutoff hemofilter versus a Standard hemofilter on the median hours of noradrenaline-free time at day 7 in critically […]
TESTING Trial Summary: Methylprednisolone in IgA Nephropathy
2022 TESTING TRIAL Effect of oral Methylprednisolone on clinical outcomes in patients with IgA nephropathy Multicenter, investigator-initiated, double-blind, randomized clinical trial Objective: To evaluate the efficacy and safety of corticosteroids in patients with IgA nephropathy at risk of progression as compared to placebo 262 (1) IgA nephropathy proven on renal biopsy (2) Proteinuria:2 1.0g/day (3) […]
SPARK Trial Summary: Furosemide in critically ill patients with early AKI
2017 SPARK TRIAL The effect of low-dose furosemide in critically illl patients with early acute kidney injury (AKI) Pilot, multicenter, randomized, double-blinded, placebo-controlled trial Objective: To evaluate the impact of furosemide in early AKI on worsening AKI, kidney recovery and RRT use as compared to placebo. 73 Patients > 18 years with RISK RIFLE category […]